Johnson & Johnson (JNJ)

As the megacap tech trade sputters, one attractive fund already owns what's leading instead -- and it's beating the market this year.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot.

Johnson & Johnson stock makes good drugs, but it's valuation isn't great.

Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.

Johnson & Johnson is a healthcare giant, but an opportunity to invest in the United States and a plethora of big products suggest it still has growth appeal.

Their dividends are about as safe as they come.

Low-risk stocks are back in vogue.

Long-term investors should skip the SpaceX roller coaster, and pivot toward these three Dividend Kings instead.

Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.

Young adults with median earnings can build sizable portfolios that pay a hefty amount of passive income by retirement.

These well-established companies are on track to deliver more growth.

In an unstable market, these three companies offer investors a chance to own durable consumer businesses that generate steady growth regardless of economic headlines.

Bear markets are a part of investing life, but you can prepare for them ahead of time.